

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
March 29, 2011**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

Onyx Pharmaceuticals, Inc.

File No. 000-28298 - CF#26526

Onyx Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed May 10, 2006 and initially filed with a Form SB-2 (333-3176-LA) on April 2, 1996.

Based on representations by Onyx Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.1	through March 29, 2016
Exhibit 10.1(i)	through March 29, 2016
Exhibit 10.2	through November 30, 2015

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Michael Seaman
Special Counsel